---
id: 089
title: Clostridioides difficile Infection Treatment
category: clinical_syndromes
subcategory: c_difficile
tags: [C-difficile, CDI, vancomycin, fidaxomicin, bezlotoxumab, FMT]
difficulty: medium
---

## Question

How is C. difficile infection treated? Use the **"Vanc > Metro, Fidax for Recurrence, FMT for Multiple"** principle.

## Answer

### **Treatment by Severity:**

**Non-Severe (WBC <15,000, Cr <1.5):**
- **Vancomycin** 125mg PO QID × 10 days (preferred) OR
- **Fidaxomicin** 200mg PO BID × 10 days (if recurrent)

**Severe (WBC ≥15,000 OR Cr ≥1.5):**
- **Vancomycin** 125mg PO QID × 10 days

**Fulminant (hypotension, shock, ileus, megacolon):**
- **Vancomycin** 500mg PO/NG QID + **metronidazole** 500mg IV q8h
- If ileus: Add **vancomycin 500mg per rectum** (retention enema) q6h
- **Surgery** if perforation, toxic megacolon unresponsive

### **Recurrent CDI:**

**First Recurrence:**
- **Fidaxomicin** 200mg PO BID × 10 days (preferred) OR
- **Vancomycin taper** (125mg QID → BID → daily → every 2-3 days over 6 weeks)
- Consider **bezlotoxumab** (monoclonal antibody) × 1 dose

**Multiple Recurrences (≥2):**
- **Fecal microbiota transplantation (FMT)** (most effective, 80-90% cure) OR
- **Fidaxomicin** OR
- **Vancomycin taper + pulse**

## Key Points

### **Why Vancomycin Over Metronidazole:**
- **2018 IDSA guidelines:** Vancomycin or fidaxomicin preferred
- **Metronidazole:** Inferior efficacy, neurotoxicity risk
- **Only use metronidazole:** If vanc/fidax unavailable OR add to vanc in fulminant

### **Bezlotoxumab:**
- **Monoclonal antibody** against C. diff toxin B
- **Single IV dose** (10 mg/kg)
- **Reduces recurrence** by ~40% (not initial cure)
- **Use:** High risk for recurrence (≥2 prior episodes, age >65, immunosuppressed)

### **Fecal Microbiota Transplantation (FMT):**
- **Most effective** for recurrent CDI (80-90% cure)
- **Indication:** ≥2 recurrences
- **Route:** Colonoscopy, capsules, enema
- **Mechanism:** Restores gut microbiome

### **Clinical Pearls:**
- **Vancomycin PO** first-line (not metronidazole)
- **Fidaxomicin** for recurrence (lower recurrence rate than vanc)
- **FMT** for multiple recurrences (most effective)
- **Bezlotoxumab** reduces recurrence risk
- **Stop offending antibiotic** if possible

## Sources

- [IDSA/SHEA: C. difficile Guidelines 2021]

## Media

N/A
